One study on pancreatic cancer (n = 68) failed to demonstrate an association between BRG1 expression and gemcitabine response or survival,17 but the finding of a potential predictive role for SMARCA4/BRG1 in the current study merits further validation in additional patient cohorts. This evidence concerns the gene SMARCA4 and pancreatic neoplasm.